NASDAQ:TRML Tourmaline Bio Q2 2025 Earnings Report $47.89 +0.02 (+0.04%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$47.50 -0.38 (-0.80%) As of 10/7/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Tourmaline Bio EPS ResultsActual EPS-$0.90Consensus EPS -$0.94Beat/MissBeat by +$0.04One Year Ago EPSN/ATourmaline Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATourmaline Bio Announcement DetailsQuarterQ2 2025Date8/13/2025TimeBefore Market OpensConference Call DateWednesday, August 13, 2025Conference Call Time7:00AM ETUpcoming EarningsTourmaline Bio's Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Tourmaline Bio Earnings HeadlinesTourmaline Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRMLOctober 6 at 5:24 PM | businesswire.comTourmaline Bio, Inc. (NASDAQ:TRML) Receives $45.65 Consensus Price Target from AnalystsOctober 5 at 2:31 AM | americanbankingnews.comStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today. | Paradigm Press (Ad)Tourmaline Bio (TRML) Price Target Decreased by 14.70% to 48.90September 30, 2025 | msn.comNovartis announces commencement of tender offer to acquire Tourmaline BioSeptember 29, 2025 | globenewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Tourmaline Bio, Inc. (NASDAQ: TRML)September 15, 2025 | prnewswire.comSee More Tourmaline Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tourmaline Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tourmaline Bio and other key companies, straight to your email. Email Address About Tourmaline BioTourmaline Bio (NASDAQ:TRML) operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.View Tourmaline Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings PepsiCo (10/9/2025)Fastenal (10/13/2025)Wells Fargo & Company (10/14/2025)Citigroup (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)The Goldman Sachs Group (10/14/2025)BlackRock (10/14/2025)ASML (10/15/2025)Kinder Morgan (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
